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Abstract
Major depressive disorder is associated with an elevated risk of numerous metabolic disturbances,
including obesity, metabolic syndrome, insulin-dependent diabetes mellitus type II, and death after
myocardial infarction. Several recent papers also indicate that disturbances of mood may alter
peripheral signaling pathways that regulate metabolic processes, including those involving leptin and
ghrelin.
Introduction and context
The prevalence of obesity and associated disorders,
including diabetes mellitus type II (DMII) and coronary
artery disease, has dramatically risen in recent years.
Obesity is quickly approaching tobacco use as the
leading cause of preventable death in the US [1]. A
growing body of literature indicates that obesity and
metabolic disorders develop from a complex interplay
between genetic susceptibility and environmental fac-
tors. Of the known causes, psychological stress is now
thought to be an important environmental risk factor.
For example, in New Zealand, a longitudinal study of
1,037 children found that girls who suffered from major
depression in late adolescence had a 2.3-fold increased
risk of obesity later in adulthood [2]. In addition to
increasing the risk of becoming obese, major depressive
disorder (MDD) is frequently associated with other
comorbidities, including the metabolic syndrome, ather-
osclerosis, and diabetes.
While the occurrence of MDD after myocardial infarction
(MI) has long been appreciated as a leading risk factor for
post-MI mortality, the causal factor of the association is
not clear [3]. Two large trials, SADHART (Sertraline
AntiDepressant Heart Attack Trial) and ENRICHD
(ENhancing Recovery in Coronary Heart Disease),
attempted to determine the effect of treating post-MI
MDD with medication and psychotherapy, respectively.
While both treatment options were deemed to be safe
and effective for the treatment of MDD in cardiac
patients, the studies were underpowered to identify a
mortality benefit. Thus, it is unclear whether the presence
of MDD itself worsened cardiac outcome or whether
MDD was more likely to occur in patients destined for
negative outcomes [4].
Finally, many researchers have examined the complex
association of MDD and DMII. Ali and colleagues [5]
performed a meta-analysis of 10 studies that included
over 51,000 patients and found higher rates of MDD in
patients with diabetes than in patients without diabetes.
In an attempt to determine the direction of association
between MDD and DMII, Golden and colleagues [6]
performed a large bidirectional study. The authors
reported that, in patients without a diagnosis of diabetes
at baseline, the presence of depressive symptoms slightly
increased the risk of later developing diabetes after
3.2 years. Importantly, they also reported that the reverse
association was true: a diagnosis of DMII increased the
risk of having depressive symptoms at follow-up 3.1 years
later. This study suggests a bidirectional association
between mood disorders and diabetes, with the presence
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the clear link between MDD and metabolic disorders in
epidemiologic studies, relatively little is known about the
mechanism that underlies this association [7]. Recent
results have begun to inform us of the mechanism of this
mind-body connection.
Major recent advances
Leptin, a hormone produced by adipose tissue, is well
known for regulating food intake and body weight [8].
Recently, Lu and colleagues [9] proposed a role for leptin
action in mood regulation. They reported a reduction in
leptin levels after chronic unpredictable stress (CUS), a
rodent model of stress-induced anhedonia. Furthermore,
acute administration of leptin reversed the deficits
observed in sucrose preference after CUS. Finally, in the
forced swim test, a model of behavioral despair in
rodents, leptin administration into the hippocampus
caused an antidepressant-like effect.
Other recent studies suggest a potential role for leptin in
mediating reward processing via direct action on the
dopamine neurons of the ventral tegmental area (VTA).
For example, Fulton and colleagues [10] reported that
leptin deficiency blunted the locomotor response of
mice to amphetamine injection. Dopamine levels as well
as electrically stimulated dopamine release were also
lower in leptin-deficient mice. In addition, Hommel and
colleagues [11] demonstrated that direct infusion of
leptin into the VTA suppresses feeding, while reduction
of leptin receptor levels in the VTA by small interfering
RNA increases food intake and locomotor activity.
Recently, our group suggested a potential role for ghrelin,
a stomach-derived proappetite hormone, in the regula-
tion of stress-induced changes in feeding and behavior
[12]. Chronic social defeat stress (CSDS) is a preclinical
model of chronic stress that models features of certain
psychiatric disorders, including MDD, social anxiety, and
post-traumatic stress disorder [13,14]. Following expo-
sure to CSDS, mice display persisting deficits in social
interaction as well as increased food consumption.
During the same time frame, ghrelin levels increase and
remain elevated for up to 1 month after the last stressor.
Notably, mice lacking the ghrelin receptor exhibit
reduced hyperphagia compared with wild-type mice
exposed to social stress. However, growth hormone
secretagogue receptor (GHSR)-null mice displayed wor-
sened social isolation after CSDS, indicating that ghrelin
signaling may be involved in distinct adaptations to
stress. Finally, peripheral administration of ghrelin to
wild-type mice produced anxiolytic-like and antidepres-
sant-like responses in the elevated plus maze and the
forced swim test.
The site of ghrelin action on mood is of considerable
interest. Like leptin signaling, ghrelin signaling is
thought to occur in the hippocampus and the VTA, two
key areas regulating mood and reward. Diano and
colleagues [15] reported that ghrelin signaling improves
memory and spatial learning by increasing dendritic
spine synapse density and long-term potentiation.
Abizaid and colleagues [16] reported that ghrelin
signaling in the VTA increased dopamine neuron activity
and promoted feeding. Infusion of a ghrelin receptor
antagonist directly into the VTA also inhibited the effect
of peripheral administration of ghrelin on feeding,
indicating that the VTA is a key target of ghrelin-
mediated food intake.
Future directions
Metabolic diseases are frequently comorbid with mental
illness, although the mechanism of this association is
unknown. Recent research using preclinical models of
stress has revealed an unexpected role for the peripheral
hormones leptin and ghrelin in the regulation of mood
symptoms. These findings now suggest a possible
mechanism linking metabolic dysregulation and chronic
stress. Future studies will need to determine whether a
stress-induced decrease in leptin and increase in ghrelin
signaling contribute to the development of obesity,
diabetes, metabolic syndrome, and coronary heart
disease. Furthermore, the neuronal targets of leptin and
ghrelin action on mood need to be elucidated. Prelimin-
arywork indicates that thehippocampusand VTAmaybe
key targets for their action, although this hypothesis must
be confirmed by direct genetic targeting of leptin and
ghrelin receptor signaling in these specific neurons.
Abbreviations
CSDS, chronic social defeat stress; CUS, chronic unpre-
dictable stress; DMII, diabetes mellitus type II;
ENRICHD, ENhancing Recovery in Coronary Heart
Disease; GHSR, growth hormone secretagogue receptor;
MDD, major depressive disorder; MI, myocardial infarc-
tion; SADHART, Sertraline AntiDepressant Heart Attack
Trial; VTA, ventral tegmental area.
Competing interests
The authors declare that they have no competing
interests.
Acknowledgements
The authors would like to acknowledge the following for
their financial support: National Institutes of Health
(NIH) grants K08 MH084058-1A1, RL1 DK081182, RL1
DK081185, the NARSAD Young Investigator Award, and
the Disease-Oriented Clinical Scholars Program from UT
Southwestern.
Page 2 of 3
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:63 http://F1000.com/Reports/Biology/content/1/63References
1. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ,
Ezzati M: The preventable causes of death in the United
States: comparative risk assessment of dietary, lifestyle, and
metabolic risk factors. PLoS Med 2009, 6:e1000058.
2. Richardson LP, Davis R, Poulton R, McCauley E, Moffitt TE, Caspi A,
Connell F: A longitudinal evaluation of adolescent depression
and adult obesity. Arch Pediatr Adolesc Med 2003, 157:739-45.
3. Plante GE: Depression and cardiovascular disease: a reciprocal
relationship. Metabolism 2005, 54(5 Suppl 1):45-8.
4. Joynt KE, O’Connor CM: Lessons from SADHART, ENRICHD,
and other trials. Psychosom Med 2005, 67(Suppl 1):S63-6.
5. AliS,StoneMA,PetersJL,DaviesMJ,KhuntiK:Theprevalenceofco-
morbiddepression inadultswith Type2 diabetes:a systematic
review and meta-analysis. Diabet Med 2006, 23:1165-73.
6. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez
Roux AV, Lee HB, Lyketsos C: Examining a bidirectional
association between depressive symptoms and diabetes.
JAMA 2008, 299:2751-9.
F1000 Factor 6.0 Must Read
Evaluated by Antonio Campayo 16 Sept 2008
7. Kishi T, Elmquist JK: Body weight is regulated by the brain: a link
between feeding and emotion. Mol Psychiatry 2005, 10:132-46.
8. Friedman JM: Leptin at 14 y of age: an ongoing story. Am J Clin
Nutr 2009, 89:973S-9S.
9. Lu XY, Kim CS, Frazer A, Zhang W: Leptin: a potential novel
antidepressant. Proc Natl Acad Sci U S A 2006, 103:1593-8.
10. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-
Flier E, Flier JS: Leptin regulation of the mesoaccumbens
dopamine pathway. Neuron 2006, 51:811-22.
F1000 Factor 4.8 Must Read
Evaluated by Claire-Dominique Walker 17 Nov 2006, Sadaf Farooqi
06 Feb 2007
11. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB,
Thurmon JJ, Marinelli M, DiLeone RJ: Leptin receptor signaling in
midbrain dopamine neurons regulates feeding. Neuron 2006,
51:801-10.
F1000 Factor 4.8 Must Read
Evaluated by Kent Berridge 27 Nov 2006, Claire-Dominique Walker
01 Dec 2006, Laurence Tecott 11 Jan 2007
12. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG,
Jung S, Birnbaum S, Yanagisawa M, Elmquist JK, Nestler EJ, Zigman JM:
The orexigenic hormone ghrelin defends against depressive
symptoms of chronic stress. Nat Neurosci 2008, 11:752-3.
13. Avgustinovich DF, Gorbach OV, Kudryavtseva NN: Comparative
analysis of anxiety-like behavior in partition and plus-maze
tests after agonistic interactions in mice. Physiol Behav 1997,
61:37-43.
14. Krishnan V, Berton O, Nestler E: The use of animal models in
psychiatric research and treatment. Am J Psychiatry 2008,
165:1109.
1 5 . D i a n oS ,F a r rS A ,B e n o i tS C ,M c N a yE C ,d aS i l v aI ,H o r v a t hB ,
Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto S,
Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschöp MH,
Horvath TL: Ghrelin controls hippocampal spine synapse
density and memory performance. Nat Neurosci 2006,
9:381-8.
F1000 Factor 4.8 Must Read
Evaluated by Laurence H Tecott 28 Apr 2006, Tallie Baram 29 Aug
2006
16. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E,
Elsworth JD, Roth RH, Sleeman MW, Picciotto MR, Tschöp MH,
Gao XB, Horvath TL: Ghrelin modulates the activity and
synaptic input organization of midbrain dopamine neurons
while promoting appetite. J Clin Invest 2006, 116:3229-39.
F1000 Factor 6.0 Must Read
Evaluated by Stephen Woods 24 Oct 2006
Page 3 of 3
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:63 http://F1000.com/Reports/Biology/content/1/63